Agile Therapeutics, Inc.

Agile Therapeutics, Inc. (NASDAQ: AGRX) is a women's healthcare company that aims to satisfy women's unmet medical requirements. Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, the company's initial product, is non-daily prescription contraception. Twirla is based on Skinfusion, a groundbreaking transdermal patch that delivers medication through the skin. 

Why Should Investors Make an Exit?

• Lackluster Financials: AGRX reported revenue first time in 9MFY21 (ended September 30, 2021) to the tune of USD 2.59 million. The company witnessed an increase in net losses to USD 51.54 million during 9MFY21 vs. USD 34.23 million during 9MFY20.
• Stresses Margin Profile: In Q3FY21, AGRX’s reported gross margin was -110.6% vs. the industry median of 65.6% and reported net margin of -1,225.6% in the period under consideration which was lower than the industry median of 15.9% .
• Leveraged Balance Sheet: The company is more exposed to balance sheet risk than its peers, with a Debt/Equity ratio of 1.54x as of September 30, 2021, compared to the industry norm of 0.41x. Furthermore, its long-term debt-to-total-capital ratio was 60.6%, compared to the industry average of 26.4% for the same period. These leveraged financials put the corporation at risk of huge swings due to the slightest adjustment in interest rates.
• Product Concentration Risk: Apart from Twirla, AGRX currently has no commercially marketed products. Product sales have only made a small profit thus far. Excessive reliance too much on a single product could harm the financials.
• Weak Liquidity Profile: The company's current ratio at the end of Q3FY21 is 2.27x, compared to the industry median of 3.05x. This implies relatively lackluster liquidity profile against the industry median.
• Technical weakness: On the daily chart, AGRX prices are sustaining below the downward sloping trend line and facing the resistance of the same. Furthermore, the momentum oscillator RSI (14-period) is trading at ~34.49 level, reversing from the higher levels. However, on the daily chart the prices are trading below the trend-following indicators 21-period and 50- period SMA, which may act as a resistance level for the stock. An important support level for the stock, is placed at USD 0.22 while the key resistance level is placed at USD 0.39.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

AGRX's share price has declined 81.70% in the past nine months and is currently leaning towards the lower band of the 52-week range of USD 0.25 to USD 2.47. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 0.24.

 Considering the company's highly leveraged balance sheet, lackluster financials, weak liquidity profile, stressed margins, current valuation and associated risks. we recommend a "Sell" rating on the stock at the closing price of USD 0.28, up 1.63% as of March 04, 2022.

Three-Year Technical Price Chart (March 04, 2022). Source: REFINITIV, Analysis by Kalkine Group

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.